·
Parkinsonism:
·
Parkinsonism is a
neurodegenerative disorder
·
Loss of neuron in basal ganglia (SNPC) that affect movement control (motor
functions)
·
Degeneration of Dopaminergic
neurons in Substantia Nigra Pars Compacta (SNPC)
·
Decrease in level of Dopamine.
·
Imbalance of Dopamine
(inhibitory) and acetylcholine (Excitatory) in Straitum part.
·
Symptoms: Bradykinesia,
tremors, mask like face, abnormal gait and posture, rigidity,
hypersalivation.
|
||||||||||
N-methy-4-phenyl tetrahydropyridine
(MPTP) toxin induce parkinsonism
|
||||||||||
Classification
|
||||||||||
Drugs altering dopaminergic system
|
Drugs altering cholinergic system
|
|||||||||
1. COMT inhibitor
·
Peripheral COMT inhibitor-Entacapone
·
Peripheral and central COMT inhibitor-Tolcapone
2.
Dopaminergic agonist-
·
Ergot derivative-
Bromocriptine, Pergolide
·
Non ergot derivative-Apomorphine,
Pramipexole, Ropinirole, Rotigotine
3.
Dopamine precursor- Levodopa
4.
Nmda receptor antagonist- Amantadine
5.
Peripheral decarboxylase inhibitors-Benserazide,
Carbidopa
6.
Selective MAO-B inhibitor-Selegeline, Rasagiline
|
1.
Central anticholinergics- Benzhexol,
Biperiden, Procyclidine, Benztropin
2.
Antihistaminics- Orphenadrine, Promethazine
|
|||||||||
Levodopa
|
·
Dopamine is hydrophilic in
nature so not cross BBB- that’s why we use prodrug levodopa (lipophilic)
·
Peripherally levodopa is
metabolised by dopa decarboxylase, therefore only 4-5% levodopa reach in
brain
·
To decrease peripheral
metabolism: levodopa always used in combination with dopa decarboxylase inhibitors
(Carbidopa, Benserazide)
·
Levodopa cause adverse
effects like postural hypotension, nausea, vomiting, arrythmia, psychosis
(hallucination), dyskinesia
·
Adverse effect of Levodopa
like postural hypotension, nausea, vomiting, arrythmia are decreased by Carbidopa
(by inhibiting peripheral conversion) but dyskinesia, psychosis not cured.
·
Pyridoxine (vitamin b6)
decrease effectiveness of Levodopa
·
Brown discolouration of urine
and saliva
|
|||||||||
|
COMT
·
Entcapone (short acting)
inhibit COMT enzyme peripherally only.
·
Tolcapone (long acting)
inhibit COMT enzyme both peripherally as well as centrally
·
Tolcapone cause
hepatotoxicity
·
COMT inhibitors cause
diarrhoea and orange red discolouration of urine.
|
|||||||||
Selective MAO-B inhibitors
|
·
These are the irreversible inhibitor of MAO-B
·
At low dose they only inhibit
MAO-B, but at high dose they also inhibit MAO-A, so there is chances of
cheese reaction and serotonin syndrome with TCA antidepressants.
·
They have some
neuroprotective effect (decrease neurodegeneration)
|
|||||||||
Dopamine agonist
|
|
|||||||||
NMDA receptor antagonist
|
·
Inhibit glutamate activity by
blocking NMDA receptor
·
Increase dopamine release as
well
·
Also have anticholinergic
property
·
It is an antiviral agent (for
influenza)
·
Cause ankle edema and livedo reticularis
(bluish discolouration)
|
|||||||||
Drugs altering central cholinergic level
|
·
These are the 1st
choice of drug in drug induced parkinsonism promethazine and orphenadrine are
1st generation antihistaminic drugs which have high
anticholinergic property.
·
Affect memory, cause urinary
retention, blurred vision.
|
|||||||||
\
|
||||||||||
Saturday, 4 February 2017
Anti Parkinsonian Drugs
Labels:
Parkinsonism
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment